Skip to main content
Premium Trial:

Request an Annual Quote

Fulgent Inks $125M Equity Distribution Agreement With Piper Sandler

NEW YORK – Fulgent disclosed in a filing with the US Securities and Exchange Commission today that has signed an equity distribution agreement with investment bank Piper Sandler to sell up to $125 million worth of its common stock.

The sale of the shares are pursuant to a shelf registration filed earlier this year. The maximum proposed offering under that registration is $300 million.

Under the agreement, Piper Sandler may sell the shares from time to time through an at-the-market offering. The bank is entitled to a commission at a rate of up to 3 percent of the gross proceeds from each sale of shares under the deal.

Fulgent noted that it has no obligation to sell any of the shares and may at any time suspend offers under the equity distribution agreement. It said that it would use any net proceeds for working capital and general corporate purposes.

Based in Temple City, California, Fulgent offers clinical genetic testing using next-generation sequencing. 

The firm earlier this week also filed a prospectus for the sale of 1,906,338 shares of common stock that may be reoffered or resold from time to time by certain selling stockholders. Fulgent wouldn't receive any proceeds from the sales of those shares.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more